Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer

International Journal of Computer Assisted Radiology and Surgery

Volumn 8, Issue 2, 2013, Pages 181-191

  Zhang, Hao ^a,b   Wroblewski, Kristen ^b   Appelbaum, Daniel ^b   Pu, Yonglin ^b  

^a LANZHOU UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

F 18 Fluorodeoxyglucose (FDG); Non small cell lung cancer; Positron emission tomography (PET); Tumor burden

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER PROGRAM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; THORACOTOMY; TUMOR VOLUME; WHOLE BODY PET;

EID: 84878882333     PISSN: 18616410     EISSN: 18616429     Source Type: Journal    
DOI: 10.1007/s11548-012-0749-7     Document Type: Article

References (38)

1. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8): S4-S66
2. Maldonado A, Gonzalez-Alenda FJ, Alonso M, Sierra JM (2007) Usefulness of positron emission tomography-computed tomography in respiratory medicine. Arch Bronconeumol 43: 562-572
3. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL (1999) Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 213: 521-525
4. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ (1994) The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. J Nucl Med 35: 1308-1312
5. Weber WA, Schwaiger M, Avril N (2000) Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 27: 683-687
6. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, Le QT, Wakelee HA, Donington JS, Graves EE, Loo BW Jr. (2007) Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 69: 328-333
7. Raben D, Chen C, Loo B, Graves E, Kavanagh B (2009) Metabolic tumor volume and oropharynx subsite as prognostic factors in advanced head and neck cancer. Int J Radiat Oncol 75: S412
8. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2: 159-171
9. Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le Q-T, Wakelee HA, Graves EE, Loo BW (2012) Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer 13: 52-58
10. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y (2012) Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 39(1): 27-38
11. Liao S, Penney BC, Zhang H, Suzuki K, Pu Y (2012) Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in stage IV nonsurgical small-cell lung cancer. Acad Radiol 19(1): 69-77
12. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111: 1710-1717
13. Grivaux M, Zureik M, Marsal L, Asselain B, Peureux M, Chavaillon JM, Prud'homme A, Carbonnelle M, Goarant E, Maury B, Bedossa A, Blanchon F (2009) Five year survival for lung cancer patients managed in general hospitals. Rev Mal Respir 26: 37-44
14. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350: 379-392
15. Socinski MA, Morris DE, Masters GA, Lilenbaum R (2003) Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123: 226S-243S
16. Borst GR, Belderbos JSA, Boellaard R, Comans EFI, de Jaeger KD, Lammertsma AA, Lebesque JV (2005) Standardized FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 41: 1533-1541
17. Davies A, Tan C, Paschalides C, Barrington S, O'Doherty M, Utley M, Treasure T (2007) FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 55: 75-78
18. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, Rupa D, Pastorekova S, Stroobants S, Buell U, Lambin P, Vansteenkiste J, De Ruysscher D (2007) The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43: 1392-1398
19. Geus-Oei LF, Oyen WJ (2008) Predictive and prognostic value of FDG-PET. Cancer Imaging 8: 70-80
20. UyBico SJ, Wu CC, Suh RD, Le NH, Brown K, Krishnam MS (2010) Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 30: 1163-1181
21. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Vanden Abbeele A, Yap J, Sullivan D (2006) Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 47: 1059-1066
22. Werner-Wasik M, Nelson AD, Choi W, Arai Y, Faulhaber PF, Kang P, Almeida FD, Xiao Y, Ohri N, Brockway KD, Piper JW, Nelson AS (2012) What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 82(3): 1164-1171
23. Houseni M, Chamroonrat W, Zhuang J, Gopal R, Alavi A, Zhuang H (2010) Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med 51: 535-542
24. Cox DR (1972) Regression models and life-tables (with discussion). J R Stat Soc Series B (Methodol) 34: 817-220
25. Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526
26. Gönen M, Heller G (2005) Concordance probability and discriminatory power in proportional hazards regression. Biometrika 92: 965-970
27. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714
28. Pelosi E, Billè A, Skanjeti A, Errico L, Arena V, Ardissone F, Borasio P, Mancini M (2011) Prognostic role of the PET parameter maximum standardized uptake value in non small cell lung cancer: analysis in tumour of diameter ≥ and < 25 mm. Q J Nucl Med Mol Imaging 55: 72-80
29. Oven UBB, Gumus M, Bilici A, Seker M, Ustaalioglu R, Kefeli U, Salepci T, Canpolat N, Mayadagli A, Dogusoy I (2010) Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience. J Balkan Union Oncol 15: 529-536
30. max measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. Lung Cancer 71: 49-54
31. Um SW, Kim H, Koh WJ, Suh GY, Chung MP, Kwon OJ, Choi JY, Han J, Lee KS, Kim J (2009) Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Thorac Oncol 4: 1331-1336
32. Nair VS, Barnett PG, Ananth L, Gould MK (2010) PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. Chest 137: 1150-1156
33. Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, Poncelet AJ (2008) Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 33: 819-823
34. Nambu A, Kato S, Sato Y, Okuwaki H, Nishikawa K, Saito A, Matsumoto K, Ichikawa T, Araki T (2009) Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET. Ann Nucl Med 23: 269-275
35. Liu S, Cheng H, Yao S, Wang C, Han G, Li X, Liu C (2010) The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features. Ann Nucl Med 24: 541-547
36. Visbal AL, Williams BA, Nichols FC 3rd, Marks RS, Jett JR, Aubry MC, Edell ES, Wampfler JA, Molina JR, Yang P (2004) Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 78: 209-215
37. Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan KP (2010) Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer 68: 398-402
38. Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, Miyamori I, Sasaki M, Yonekura Y (2003) 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 44: 540-548